Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases
Abstract
:1. Introduction
2. Parkinson’s Disease Models
2.1. Neurotoxin-Induced PD Models in Zebrafish and Medaka
2.1.1. MPTP
2.1.2. 6-OHDA
2.1.3. Paraquat
2.1.4. Rotenone
2.2. Genetic PD Models in Zebrafish and Medaka
2.2.1. Parkinson’s Disease Protein 2 (PARK2)
2.2.2. PTEN (Phosphatase/Tensin Homolog)-Induced Kinase 1 (Pink1)
2.2.3. LRRK2 (Leucine-Rich Repeat Kinase 2)
2.2.4. PARK7 (Parkinson’s Disease Protein 7)
2.2.5. Other Genes
3. Alzheimer’s Disease Models
3.1. Neurotoxic Agents-Induced AD Model in Zebrafish
3.2. Metals and AD in Zebrafish
3.3. Genetic Technology-Mediated AD Model in Zebrafish
4. Huntington’s Disease Models
5. Other Neurodegenerative Disease Models
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Heemels, M.T. Neurodegenerative diseases. Nature 2016, 539, 179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gitler, A.D.; Dhillon, P.; Shorter, J. Neurodegenerative disease: Models, mechanisms, and a new hope. Dis. Models Mech. 2017, 10, 499–502. [Google Scholar] [CrossRef] [Green Version]
- Fernaández-Trapero, M.; Espejo-Porras, F.; Rodrıguez-Cueto, C.; Coates, J.R.; Peérez-Díaz, C.; De Lago, E.; Fernaández-Ruiz, J. Upregulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Dis. Model Mech. 2017, 10, 551–558. [Google Scholar] [CrossRef] [Green Version]
- Snyder, B.R.; Chan, A.W.S. Progress in Developing Transgenic Monkey Model for Huntington’s Disease. J. Neural Transm. 2018, 125, 401–417. [Google Scholar] [CrossRef] [PubMed]
- Story, B.D.; Miller, M.E.; Bradbury, A.M.; Million, E.D.; Duan, D.; Taghian, T.; Faissler, D.; Fernau, D.; Beecy, S.J.; Gray-Edwards, H.L. Canine Models of Inherited Musculoskeletal and Neurodegenerative Diseases. Front. Vet. Sci. 2020, 7, 80. [Google Scholar] [CrossRef] [Green Version]
- Bolus, H.; Crocker, K.; Boekhoff-Falk, G.; Chtarbanova, S. Modeling Neurodegenerative Disorders in Drosophila melanogaster. Int. J. Mol. Sci. 2020, 21, 3055. [Google Scholar] [CrossRef] [PubMed]
- Horzmann, K.A.; Freeman, J.L. Making waves: New developments in toxicology with the zebrafish. Toxicol. Sci. 2018, 163, 5–12. [Google Scholar] [CrossRef] [Green Version]
- Paone, C.; Diofano, F.; Park, D.D.; Rottbauer, W.; Just, S. Genetics of cardiovascular disease: Fishing for causality. Front. Cardiovasc. Med. 2018, 5, 60. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vaz, R.L.; Outeiro, T.F.; Ferreira, J.J. Zebrafish as an animal model for drug discovery in parkinson’s disease and other movement disorders: A systematic review. Front. Neurol. 2018, 9, 347. [Google Scholar] [CrossRef] [PubMed]
- Saleem, S.; Kannan, R.R. Zebrafish: An emerging real-time model system to study Alzheimer’s disease and neurospecific drug discovery. Cell Death Discov. 2018, 4, 45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Furutani-Seiki, M.; Wittbrodt, J. Medaka and zebrafish, an evolutionary twin study. Mech. Dev. 2004, 121, 629–637. [Google Scholar] [CrossRef] [PubMed]
- Dang, M.; Henderson, R.E.; Garraway, L.A.; Zon, L.I. Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies. Dis. Model Mech. 2016, 9, 811–820. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matsuzaki, Y.; Hosokai, H.; Mizuguchi, Y.; Fukamachi, S.; Shimizu, A.; Saya, H. Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs. PLoS ONE 2013, 8, e54424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fior, R.; Póvoa, V.; Mendes, R.V.; Carvalho, T.; Gomes, A.; Figueiredo, N.; Ferreira, M.G. Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. Proc. Natl. Acad. Sci. USA 2017, 114, E8234–E8243. [Google Scholar] [CrossRef] [Green Version]
- Howe, K.; Clark, M.D.; Torroja, C.F.; Torrance, J.; Berthelot, C.; Muffato, M.; Collins, J.E.; Humphray, S.; McLaren, K.; Matthews, L.; et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013, 496, 498–503. [Google Scholar] [CrossRef] [Green Version]
- Apfeld, J.; Alper, S. What Can We Learn About Human Disease from the Nematode C. elegans? Methods Mol. Biol. 2018, 1706, 53–75. [Google Scholar] [CrossRef]
- Yamaguchi, M.; Yoshida, H. Drosophila as a Model Organism. Adv. Exp. Med. Biol. 2018, 1076, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.S.; Im, S.H.; Yang, J.Y.; Lee, Y.R.; Kim, G.R.; Chae, J.S.; Shin, D.S.; Song, J.S.; Ahn, S.; Lee, B.H.; et al. Zebrafish as a Screening Model for Testing the Permeability of Blood-Brain Barrier to Small Molecules. Zebrafish 2017, 14, 322–330. [Google Scholar] [CrossRef] [PubMed]
- Panula, P.; Chen, Y.C.; Priyadarshini, M.; Kudo, H.; Semenova, S.; Sundvik, M.; Sallinen, V. The comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human neuropsychiatric diseases. Neurobiol. Dis. 2010, 40, 46–57. [Google Scholar] [CrossRef] [PubMed]
- Matsui, H.; Uemura, N.; Yamakado, H.; Takeda, S.; Takahashi, R. Exploring the pathogenetic mechanisms underlying Parkinson’s disease in medaka fish. J. Parkinsons Dis. 2014, 4, 301–310. [Google Scholar] [CrossRef] [PubMed]
- Wittbrodt, J.; Shima, A.; Schartl, M. Medaka—a model organism from the Far East. Nat. Rev. Genet. 2002, 3, 53–64. [Google Scholar]
- Stewart, A.M.; Braubach, O.; Spitsbergen, J.; Gerlai, R.; Kalueff, A.V. Zebrafish models for translational neuroscience research: From tank to bedside. Trends Neurosci. 2014, 37, 264–278. [Google Scholar] [CrossRef] [Green Version]
- GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018, 17, 939–953. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Savica, R.; Grossardt, B.R.; Bower, J.H.; Ahlskog, J.E.; Boeve, B.F.; Graff-Radford, J.; Rocca, W.A.; Mielke, M.M. Survival and Causes of Death among People with Clinically Diagnosed Synucleinopathies with Parkinsonism: A Population-Based Study. JAMA Neurol. 2017, 74, 839–846. [Google Scholar] [CrossRef]
- Darweesh, S.K.L.; Raphael, K.G.; Brundin, P.; Matthews, H.; Wyse, R.K.; Chen, H.; Bloem, B.R. Parkinson Matters. J. Parkinsons Dis. 2018, 8, 495–498. [Google Scholar] [CrossRef] [Green Version]
- James, S.L.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858. [Google Scholar] [CrossRef] [Green Version]
- Roth, G.A.; Abate, D.; Abate, K.H.; Abay, S.M.; Abbafati, C.; Abbasi, N.; Abbastabar, H.; Abd-Allah, F.; Abdela, J.; Abdelalim, A.; et al. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1736–1788. [Google Scholar] [CrossRef] [Green Version]
- Rocca, W.A. The burden of Parkinson’s disease: A worldwide perspective. Lancet Neurol. 2018, 17, 928–929. [Google Scholar] [CrossRef] [Green Version]
- Pirtošek, Z.; Bajenaru, O.; Kovács, N.; Milanov, I.; Relja, M.; Skorvanek, M. Update on the Management of Parkinson’s Disease for General Neurologists. Parkinson’s Dis. 2020, 2020, 9131474. [Google Scholar] [CrossRef]
- Hoo, J.Y.; Kumari, Y.; Shaikh, M.F.; Hue, S.M.; Goh, B.H. Zebrafish: A Versatile Animal Model for Fertility Research. BioMed Res. Int. 2016, 2016, 9732780. [Google Scholar] [CrossRef] [Green Version]
- Rahman Khan, F.; Sulaiman Alhewairini, S. Zebrafish (Danio rerio) as a Model Organism. Curr. Trends Cancer Manag. 2019, 2019, 81517. [Google Scholar] [CrossRef] [Green Version]
- Matsui, H.; Takahashi, R. Parkinson’s disease pathogenesis from the viewpoint of small fish models. J. Neural Transm. 2018, 125, 25–33. [Google Scholar] [CrossRef] [PubMed]
- Barnhill, L.M.; Murata, H.; Bronstein, J.M. Studying the pathophysiology of Parkinson’s disease using zebrafish. Biomedicines 2020, 8, 8070197. [Google Scholar] [CrossRef]
- Lam, C.S.; Korzh, V.; Strahle, U. Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP. Eur. J. Neurosci. 2005, 21, 1758–1762. [Google Scholar] [CrossRef]
- Wasel, O.; Freeman, J.L. Chemical and genetic zebrafish models to define mechanisms of and treatments for dopaminergic neurodegeneration. Int. J. Mol. Sci. 2020, 21, 5981. [Google Scholar] [CrossRef]
- Sarath, B.N.; Murthy, C.H.L.; Kakara, S.; Sharma, R.; Brahmendra, S.C.V.; Idris, M.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine induced Parkinson’s disease in zebrafish. Proteomics 2016, 16, 1407–1420. [Google Scholar] [CrossRef] [PubMed]
- Vijayanathan, Y.; Lim, F.T.; Lim, S.M.; Long, C.M.; Tan, M.P.; Majeed, A.B.A.; Ramasamy, K. 6-OHDA-Lesioned Adult Zebrafish as a Useful Parkinson’s Disease Model for Dopaminergic Neuroregeneration. Neurotox. Res. 2017, 32, 496–508. [Google Scholar] [CrossRef] [PubMed]
- Vaz, R.L.; Sousa, S.; Chapela, D.; van der Linde, H.C.; Willemsen, R.; Correia, A.D.; Outeiro, T.F.; Afonso, N.D. Identification of antiparkinsonian drugs in the 6-hydroxydopamine zebrafish model. Pharmacol. Biochem. Behav. 2020, 189, 172828. [Google Scholar] [CrossRef] [PubMed]
- Li, M.; Zhou, F.; Xu, T.; Song, H.; Lu, B. Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway. Food Chem. Toxicol. 2018, 119, 6–13. [Google Scholar] [CrossRef]
- Cronin, A.; Grealy, M. Neuroprotective and neuro-restorative effects of minocycline and rasagiline in a zebrafish 6-hydroxydopamine model of Parkinson’s disease. Neuroscience 2017, 367, 34–46. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.H.; Souders, C.L.; Zhao, Y.H.; Martyniuk, C.J. Paraquat affects mitochondrial bioenergetics, dopamine system expression, and locomotor activity in zebrafish (Danio rerio). Chemosphere 2018, 191, 106–117. [Google Scholar] [CrossRef]
- Nellore, J.P.N. Paraquat exposure induces behavioral deficits in larval zebrafish during the window of dopamine neurogenesis. Toxicol. Rep. 2015, 2, 950–956. [Google Scholar] [CrossRef] [Green Version]
- Bortolotto, J.W.; Cognato, G.P.; Christoff, R.R.; Roesler, L.N.; Leite, C.E.; Kist, L.W.; Bogo, M.R.; Vianna, M.R.; Bonan, C.D. Long-term exposure to paraquat alters behavioral parameters and dopamine levels in adult zebrafish (Danio rerio). Zebrafish 2014, 11, 142–153. [Google Scholar] [CrossRef] [PubMed]
- Müller, T.E.; Nunes, M.E.; Menezes, C.C.; Marins, A.T.; Leitemperger, J.; Gressler, A.C.L.; Carvalho, F.B.; de Freitas, C.M.; Quadros, V.A.; Fachinetto, R.; et al. Sodium Selenite Prevents Paraquat-Induced Neurotoxicity in Zebrafish. Mol. Neurobiol. 2018, 55, 1928–1941. [Google Scholar] [CrossRef] [PubMed]
- Lv, D.J.; Li, L.X.; Chen, J.; Wei, S.Z.; Wang, F.; Hu, H.; Xie, A.M.; Liu, C.F. Sleep deprivation caused a memory defects and emotional changes in a rotenone-based zebrafish model of Parkinson’s disease. Behav. Brain Res. 2019, 372, 112031. [Google Scholar] [CrossRef] [PubMed]
- Ramli, M.D.B.C.; Hashim, N.H.B.; Uzid, M.B.M.; Weinheimeri, A.Z. Zebrafish parkinson’s model: The effects of tocotrienol rich fraction towards rotenone induced zebrafish. Int. J. Med. Toxicol. Legal Med. 2020, 23, 1–7. [Google Scholar] [CrossRef]
- Ünal, İ.; Üstündağ, Ü.V.; Ateş, P.S.; Eğilmezer, G.; Alturfan, A.A.; Yiğitbaşı, T.; Emekli-Alturfan, E. Rotenone impairs oxidant/antioxidant balance both in brain and intestines in zebrafish. Int. J. Neurosci. 2019, 129, 363–368. [Google Scholar] [CrossRef] [PubMed]
- Wang, Q.; Liu, Y.; Zhou, J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Trans. Neurodegener. 2015, 4, 40–42. [Google Scholar] [CrossRef] [Green Version]
- Ge, P.; Dawson, V.L.; Dawson, T.M. PINK1 and Parkin mitochondrial quality control: A source of regional vulnerability in Parkinson’s disease. Mole Neurodegener. 2020, 15, 7. [Google Scholar] [CrossRef] [Green Version]
- Flinn, L.; Mortiboys, H.; Volkmann, K.; Kster, R.W.; Ingham, P.W.; Bandmann, O. Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio). Brain 2009, 132, 1613–1623. [Google Scholar] [CrossRef] [Green Version]
- Sallinen, V.; Kolehmainen, J.; Priyadarshini, M.; Toleikyte, G.; Chen, Y.C.; Panula, P. Dopaminergic cell damage and vulnerability to MPTP in PINK1 knockdown zebrafish. Neurobiol. Dis. 2010, 40, 93–101. [Google Scholar] [CrossRef]
- Xi, Y.; Ryan, J.; Noble, S.; Yu, M.; Yilbas, A.E.; Ekker, M. Impaired dopaminergic neuron development and locomotor function in zebrafish with loss of pink1 function. Eur. J. Neurosci. 2010, 31, 623–633. [Google Scholar] [CrossRef] [PubMed]
- Sloan, M.; Alegre-Abarrategui, J.; Wade-Martins, R. Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models. Biochem. Soc. Trans. 2012, 40, 1080–1085. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prabhudesai, S.; Bensabeur, F.Z.; Abdullah, R.; Basak, I.; Baez, S.; Alves, G.; Holtzman, N.G.; Larsen, J.P.; Møller, S.G. LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation. J. Neurosci. Res. 2016, 94, 17–35. [Google Scholar] [CrossRef] [PubMed]
- Sheng, D.; Qu, D.; Kwok, K.H.; Ng, S.S.; Lim, A.Y.; Aw, S.S.; Lee, C.W.; Sung, W.K.; Tan, E.K.; Lufkin, T.; et al. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet. 2010, 6, e1000914. [Google Scholar] [CrossRef] [Green Version]
- Seegobin, S.P.; Heaton, G.R.; Liang, D.; Choi, I.; Blanca Ramirez, M.; Tang, B.; Yue, Z. Progress in LRRK2-Associated Parkinson’s Disease Animal Models. Front. Neurosci. 2020, 14, 674. [Google Scholar] [CrossRef]
- Hughes, G.L.; Lones, M.A.; Bedder, M.; Currie, P.D.; Smith, S.L.; Pownall, M.E. Machine learning discriminates a movement disorder in a zebrafish model of Parkinson’s disease. Dis. Model Mech. 2020, 13, dmm045815. [Google Scholar] [CrossRef]
- Bai, Q.; Mullett, S.J.; Garver, J.A.; Hinkle, D.A.; Burton, E.A. Zebrafish DJ-1 is evolutionarily conserved and expressed in dopaminergic neurons. Brain Res. 2006, 1113, 33–44. [Google Scholar] [CrossRef] [PubMed]
- Bretaud, S.; Allen, C.; Ingham, P.W.; Bandmann, O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson’s disease. J. Neurochem. 2007, 100, 1626–1635. [Google Scholar] [CrossRef] [PubMed]
- Edson, A.J.; Hushagen, H.A.; Frøyset, A.K.; Elda, I.; Khan, E.A.; Di Stefano, A.; Fladmark, K.E. Dysregulation in the Brain Protein Profile of Zebrafish Lacking the Parkinson’s Disease-Related Protein DJ-1. Mol. Neurobiol. 2019, 56, 8306–8322. [Google Scholar] [CrossRef] [PubMed]
- O’Donnell, K.C.; Lulla, A.; Stahl, M.C.; Wheat, N.D.; Bronstein, J.M.; Sagasti, A. Axon degeneration and PGC-1a-mediated protection in a zebrafish model of a-synuclein toxicity. Dis. Models Mech. 2014, 7, 571–582. [Google Scholar] [CrossRef] [Green Version]
- Keatinge, M.; Bui, H.; Menke, A.; Chen, Y.C.; Sokol, A.M.; Bai, Q.; Ellett, F.; Da Costa, M.; Burke, D.; Gegg, M.; et al. Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death. Hum. Mol. Genet. 2015, 24, 6640–6652. [Google Scholar] [CrossRef] [Green Version]
- Matsui, H.; Ito, J.; Matsui, N.; Uechi, T.; Onodera, O.; Kakita, A. Cytosolic dsDNA of mitochondrial origin induces cytotoxicity and neurodegeneration in cellular and zebrafish models of Parkinson’s disease. Nat. Commun. 2021, 12, 3101. [Google Scholar] [CrossRef]
- Noble, S.; Ismail, A.; Godoy, R.; Xi, Y.; Ekker, M. Zebrafish Parla- and Parlb-deficiency affects dopaminergic neuron patterning and embryonic survival. J. Neurochem. 2012, 122, 196–207. [Google Scholar] [CrossRef] [PubMed]
- Merhi, R.; Kalyn, M.; Zhu-Pawlowsky, A.; Ekker, M. Loss of parla Function Results in Inactivity, Olfactory Impairment, and Dopamine Neuron Loss in Zebrafish. Biomedicines 2021, 9, 205. [Google Scholar] [CrossRef]
- Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979–980. [Google Scholar] [CrossRef] [Green Version]
- Ramsay, R.R.; Dadgar, J.; Trevor, A.; Singer, T.P. Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci. 1986, 39, 581–588. [Google Scholar] [CrossRef]
- Colpo, G.D.; Ribeiro, F.M.; Rocha, N.P.; Teixeira, A.L. Study of Human Disease. Animal Models for the Study of Human Disease; Elsevier: Amsterdam, The Netherlands, 2017; pp. 1109–1129. [Google Scholar]
- Mastrangelo, L. The genetics of Parkinson disease. Adv. Genet. 2017, 98, 43–62. [Google Scholar]
- Matsui, H.; Gavinio, R.; Takahashi, R. Medaka fish Parkinson’s disease model. Exp. Neurobiol. 2012, 21, 94–100. [Google Scholar] [CrossRef] [Green Version]
- Vaccari, C.; El Dib, R.; Gomaa, H.; Lopes, L.C.; de Camargo, J.L. Paraquat and Parkinson’s disease: A systematic review and meta-analysis of observational studies. J. Toxicol. Environ. Health Part B Crit. Rev. 2019, 22, 172–202. [Google Scholar] [CrossRef]
- Nunes, M.E.; Müller, T.E.; Braga, M.M.; Fontana, B.D.; Quadros, V.A.; Marins, A.; Rodrigues, C.; Menezes, C.; Rosemberg, D.B.; Loro, V.L. Chronic Treatment with Paraquat Induces Brain Injury, Changes in Antioxidant Defenses System, and Modulates Behavioral Functions in Zebrafish. Mol. Neurobiol. 2017, 54, 3925–3934. [Google Scholar] [CrossRef] [PubMed]
- Bastías-Candia, S.; Zolezzi, J.M.; Inestrosa, N.C. Revisiting the Paraquat-Induced Sporadic Parkinson’s Disease-Like Model. Mole Neurob. 2019, 56, 1044–1055. [Google Scholar] [CrossRef]
- Robea, M.A.; Strungaru, A.; Lenzi, C.; Nicoară, M.; Ciobică, A. The Importance of Rotenone in Generating Neurological and Psychiatric Features in Zebrafish-Relevance for a Parkinson’s Disease Model. Acad. Roman Sci. 2018, 7, 55–67. [Google Scholar]
- Jiang, X.; Tang, P.C.; Chen, Q.; Zhang, X.; Fan, Y.Y.; Yu, B.C.; Gu, X.X.; Sun, Y.; Ge, X.Q.; Zhang, X.L. Cordycepin Exerts Neuroprotective Effects via an Anti-Apoptotic Mechanism based on the Mitochondrial Pathway in a Rotenone-Induced Parkinsonism Rat Model. CNS Neurol. Disord. Drug Targets 2019, 18, 609–620. [Google Scholar] [CrossRef] [PubMed]
- Askar, M.H.; Hussein, A.M.; Al-Basiony, S.F.; Meseha, R.K.; Metias, E.F.; Salama, M.M.; Antar, A.; El-Sayed, A. Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease. CNS Neurol. Disord. Drug Targets 2019, 18, 156–169. [Google Scholar] [CrossRef] [PubMed]
- Nasevicius, A.; Ekker, S.C. Effective targeted gene ‘knockdown’ in zebrafish. Nat. Genet. 2000, 26, 216–220. [Google Scholar] [CrossRef]
- Hisano, Y.; Ota, S.; Kawahara, A. Genome editing using artificial site-specific nucleases in zebrafish. Dev. Growth Differ. 2014, 56, 26–33. [Google Scholar] [CrossRef]
- Hwang, W.Y.; Fu, Y.; Reyon, D.; Maeder, M.L.; Kaini, P.; Sander, J.D.; Joung, J.K.; Peterson, R.T.; Yeh, J.R. Heritable and precise zebrafish genome editing using a CRISPR-Cas system. PLoS ONE 2013, 8, e68708. [Google Scholar] [CrossRef]
- Selvaraj, S.; Piramanayagam, S. Impact of gene mutation in the development of Parkinson’s disease. Genes Dis. 2019, 6, 120–128. [Google Scholar] [CrossRef]
- Blandini, F.; Armentero, M.T. Animal models of Parkinson’s disease. FEBS J. 2012, 279, 1156–1166. [Google Scholar] [CrossRef] [Green Version]
- Maynard, M.E.; Redell, J.B.; Kobori, N.; Underwood, E.L.; Fischer, T.D.; Hood, K.N.; LaRoche, V.; Waxham, M.N.; Moore, A.N.; Dash, P.K. Loss of PTEN-induced kinase 1 (Pink1) reduces hippocampal tyrosine hydroxylase and impairs learning and memory. Exp. Neurol. 2020, 323, 113081. [Google Scholar] [CrossRef]
- Kelm-Nelson, C.A.; Brauer, A.F.L.; Barth, K.J.; Lake, J.M.; Sinnen, M.L.K.; Stehula, F.J.; Muslu, C.; Marongiu, R.; Kaplitt, M.G.; Ciucci, M.R. Characterization of early-onset motor deficits in the Pink1−/− mouse model of Parkinson disease. Brain Res. 2018, 1680, 1–12. [Google Scholar] [CrossRef]
- Dolgacheva, L.P.; Berezhnov, A.V.; Fedotova, E.I.; Zinchenko, V.P.; Abramov, A.Y. Role of DJ-1 in the mechanism of pathogenesis of Parkinson’s disease. J. Bioenerg. Biomembr. 2019, 51, 175–188. [Google Scholar] [CrossRef] [Green Version]
- Giangrasso, D.M.; Furlong, T.M.; Keefe, K.A. Characterization of striatum-mediated behavior and neurochemistry in the DJ-1 knock-out rat model of Parkinson’s disease. Neurobiol. Dis. 2020, 134, 104673. [Google Scholar] [CrossRef] [PubMed]
- Mahul-Mellier, A.L.; Burtscher, J.; Maharjan, N.; Weerens, L.; Croisier, M.; Kuttler, F.; Leleu, M.; Knott, G.W.; Lashuel, H.A. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl. Acad. Sci. USA 2020, 117, 4971–4982. [Google Scholar] [CrossRef] [Green Version]
- Kouli, A.; Torsney, K.M.; Kuan, W.L. Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis. Parkinson’s Dis. 2018, 1, 3–26. [Google Scholar] [CrossRef]
- Toni, M.; Cioni, C. Fish Synucleins: An Update. Mar. Drugs 2015, 13, 6665–6686. [Google Scholar] [CrossRef]
- Prabhudesai, S.; Sinha, S.; Attar, A.; Kotagiri, A.; Fitzmaurice, A.G.; Lakshmanan, R.; Ivanova, M.I.; Loo, J.A.; Klärner, F.G.; Schrader, T.; et al. A novel “molecular tweezer” inhibitor of α-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 2012, 9, 464–476. [Google Scholar] [CrossRef] [Green Version]
- Van Laar, V.S.; Chen, J.; Zharikov, A.D.; Bai, Q.; Di Maio, R.; Dukes, A.A.; Hastings, T.G.; Watkins, S.C.; Greenamyre, J.T.; St Croix, C.M.; et al. α-Synuclein amplifies cytoplasmic peroxide flux and oxidative stress provoked by mitochondrial inhibitors in CNS dopaminergic neurons in vivo. Redox Biol. 2020, 37, 101695. [Google Scholar] [CrossRef]
- Gan-Or, Z.; Liong, C.; Alcalay, R.N. GBA-Associated Parkinson’s Disease and Other Synucleinopathies. Curr. Neurol. Neurosci. Rep. 2018, 18, 44. [Google Scholar] [CrossRef] [PubMed]
- Alzheimer’s Association. 2020 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2020, 16, 391–460. [Google Scholar] [CrossRef]
- Alzheimer’s Disease International. World Alzheimer Report 2019: Attitudes to Dementia; Alzheimer’s Disease International (ADI): London, UK, 2019. [Google Scholar]
- Vaz, M.; Silvestre, S. Alzheimer’s disease: Recent treatment strategies. Eur. J. Pharmacol. 2020, 887, 173554. [Google Scholar] [CrossRef] [PubMed]
- Breijyeh, Z.; Karaman, R. Comprehensive Review on Alzheimer’s Disease: Causes and Treatment. Molecules 2020, 25, 5789. [Google Scholar] [CrossRef]
- Cummings, J.L.; Cohen, S.; van Dyck, C.H.; Brody, M.; Curtis, C.; Cho, W.; Ward, M.; Friesenhahn, M.; Rabe, C.; Brunstein, F.; et al. ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology 2018, 90, e1889–e1897. [Google Scholar] [CrossRef] [Green Version]
- Alzheimer’s Association. 2018 Alzheimer’s disease facts and figures. Alzheimers Dement. 2018, 14, 367–429. [Google Scholar] [CrossRef]
- Ruhl, T.; Jonas, A.; Seidel, N.I.; Prinz, N.; Albayram, O.; Bilkei-Gorzo, A.; von der Emde, G. Oxidation and Cognitive Impairment in the Aging Zebrafish. Gerontology 2015, 62, 47–57. [Google Scholar] [CrossRef] [PubMed]
- Bhattarai, P.; Thomas, A.K.; Cosacak, M.I.; Papadimitriou, C.; Mashkaryan, V.; Zhang, Y.; Kizil, C. Modeling Amyloid-β42 Toxicity and Neurodegeneration in Adult Zebrafish Brain. J. Vis. Exp. 2017, 128, 56014. [Google Scholar] [CrossRef]
- Bhattarai, P.; Thomas, A.K.; Zhang, Y.; Kizil, C. The effects of aging on Amyloid-β42-induced neurodegeneration and regeneration in adult zebrafish brain. Neurogenesis 2017, 4, e1322666. [Google Scholar] [CrossRef]
- Rudrabhatla, P.; Pant, H.C. Role of protein phosphatase 2A in Alzheimer’s disease. Curr. Alzheimer Res. 2011, 8, 623–632. [Google Scholar] [CrossRef] [PubMed]
- Nada, S.E.; Williams, F.E.; Shah, Z.A. Development of a Novel and Robust Pharmacological Model of Okadaic Acid-induced Alzheimer’s Disease in Zebrafish. CNS Neurol. Disord. Drug Targets 2016, 15, 86–94. [Google Scholar] [CrossRef] [PubMed]
- Koehler, D.; Williams, F.E. Utilizing zebrafish and okadaic acid to study Alzheimer’s disease. Neural Regen. Res. 2018, 13, 1538–1541. [Google Scholar] [CrossRef] [PubMed]
- Muthuraman, A.; Thilagavathi, L.; Jabeen, S.; Ravishankar, S.B.; Ahmed, S.S.; George, T.; Rishitha, N.; Paramakrishnan, N. Curcumin prevents cigarette smoke extract induced cognitive impairment. Front. Biosci. 2019, 11, 109–120. [Google Scholar] [CrossRef] [PubMed]
- Muthuraman, A.; Nafisa, K.; Sowmya, M.S.; Arpitha, B.M.; Choedon, N.; Sandy, C.D.; Rishitha, N.; Johurul, I. Role of ambrisentan (selective endothelin-A receptor antagonist) on cigarette smoke exposure induced cognitive impairment in Danio rerio. Life Sci. 2019, 222, 133–139. [Google Scholar] [CrossRef] [PubMed]
- He, X.; Zhong, Z.M.; Che, Y. Locomotor activity and learning and memory abilities in Alzheimer’s disease induced by aluminum in an acid environment in zebrafish. Dongwuxue Yanjiu 2012, 33, 231–236. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Acosta, D.D.S.; Danielle, N.M.; Altenhofen, S.; Luzardo, M.D.; Costa, P.G.; Bianchini, A.; Bonan, C.D.; da Silva, R.S.; Dafre, A.L. Copper at low levels impairs memory of adult zebrafish (Danio rerio) and affects swimming performance of larvae. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2016, 185–186, 122–130. [Google Scholar] [CrossRef] [PubMed]
- Altenhofen, S.; Wiprich, M.T.; Nery, L.R.; Leite, C.E.; Vianna, M.R.M.R.; Bonan, C.D. Manganese(II) chloride alters behavioral and neurochemical parameters in larvae and adult zebrafish. Aquat. Toxicol. 2017, 182, 172–183. [Google Scholar] [CrossRef] [PubMed]
- Bai, Q.; Garver, J.A.; Hukriede, N.A.; Burton, E.A. Generation of a transgenic zebrafish model of Tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res. 2007, 35, 6501–6516. [Google Scholar] [CrossRef] [Green Version]
- Paquet, D.; Bhat, R.; Sydow, A.; Mandelkow, E.M.; Berg, S.; Hellberg, S.; Fälting, J.; Distel, M.; Köster, R.W.; Schmid, B.; et al. A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J. Clin. Investig. 2009, 119, 1382–1395. [Google Scholar] [CrossRef] [Green Version]
- Sundvik, M.; Chen, Y.C.; Panula, P. Presenilin1 regulates histamine neuron development and behavior in zebrafish, danio rerio. J. Neurosci. 2013, 33, 1589–1597. [Google Scholar] [CrossRef] [PubMed]
- van Bebber, F.; Hruscha, A.; Willem, M.; Schmid, B.; Haass, C. Loss of Bace2 in zebrafish affects melanocyte migration and is distinct from Bace1 knock out phenotypes. J. Neurochem. 2013, 127, 471–481. [Google Scholar] [CrossRef] [PubMed]
- Bejanin, A.; Schonhaut, D.R.; La Joie, R.; Kramer, J.H.; Baker, S.L.; Sosa, N.; Ayakta, N.; Cantwell, A.; Janabi, M.; Lauriola, M.; et al. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease. Brain 2017, 140, 3286–3300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lane, C.A.; Hardy, J.; Schott, J.M. Alzheimer’s disease. Eur. J. Neurol. 2018, 25, 59–70. [Google Scholar] [CrossRef] [PubMed]
- DeTure, M.A.; Dickson, D.W. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 2019, 14, 32. [Google Scholar] [CrossRef] [Green Version]
- Yamazaki, Y.; Kanekiyo, T. Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer’s Disease. Int. J. Mol. Sci. 2017, 18, 1965. [Google Scholar] [CrossRef] [Green Version]
- Mazza, M.; Marano, G.; Traversi, G.; Bria, P.; Mazza, S. Primary cerebral blood flow deficiency and Alzheimer’s disease: Shadows and lights. J. Alzheimers Dis. 2011, 23, 375–389. [Google Scholar] [CrossRef] [PubMed]
- Tcw, J.; Goate, A.M. Genetics of β-Amyloid Precursor Protein in Alzheimer’s Disease. Cold Spring Harb. Perspect. Med. 2017, 7, a024539. [Google Scholar] [CrossRef]
- Kanekiyo, T.; Bu, G. The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer’s disease. Front. Aging Neurosci. 2014, 6, 93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schubert, J.J.; Veronese, M.; Marchitelli, L.; Bodini, B.; Tonietto, M.; Stankoff, B.; Brooks, D.J.; Bertoldo, A.; Edison, P.; Turkheimer, F.E. Dynamic 11C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis. J. Nucl. Med. 2019, 60, 1452–1460. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, Z.; Xiao, N.; Chen, Y.; Huang, H.; Marshall, C.; Gao, J.; Cai, Z.; Wu, T.; Hu, G.; Xiao, M. Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits. Mol. Neurodegener. 2015, 10, 58. [Google Scholar] [CrossRef] [Green Version]
- Wyss-Coray, T. Ageing, neurodegeneration and brain rejuvenation. Nature 2016, 539, 180–186. [Google Scholar] [CrossRef]
- Jiang, T.; Tan, L.; Zhu, X.C.; Zhou, J.S.; Cao, L.; Tan, M.S.; Wang, H.F.; Chen, Q.; Zhang, Y.D.; Yu, J.T. Silencing of TREM2 exacerbates tau pathology, neurodegenerative changes, and spatial learning deficits in P301S tau transgenic mice. Neurobiol. Aging 2015, 36, 3176–3186. [Google Scholar] [CrossRef] [PubMed]
- Medina, M.; Avila, J.; Villanueva, N. Use of okadaic acid to identify relevant phosphoepitopes in pathology: A focus on neurodegeneration. Mar. Drugs 2013, 11, 1168–1656. [Google Scholar] [CrossRef] [Green Version]
- Ryu, A.R.; Kim, D.H.; Kim, E.; Lee, M.Y. The Potential Roles of Extracellular Vesicles in Cigarette Smoke-Associated Diseases. Oxid. Med. Cell Longev. 2018, 4692081. [Google Scholar] [CrossRef]
- Xu, X.; Weber, D.; Burge, R.; VanAmberg, K. Neurobehavioral impairments produced by developmental lead exposure persisted for generations in zebrafish (Danio rerio). Neurotoxicology 2016, 52, 176–185. [Google Scholar] [CrossRef] [PubMed]
- Bondy, S.C. Low levels of aluminum can lead to behavioral and morphological changes associated with Alzheimer’s disease and age-related neurodegeneration. Neurotoxicology 2016, 52, 222–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Z.; Wei, X.; Yang, J.; Suo, J.; Chen, J.; Liu, X.; Zhao, X. Chronic exposure to aluminum and risk of Alzheimer’s disease: A meta-analysis. Neurosci. Lett. 2016, 610, 200–206. [Google Scholar] [CrossRef] [PubMed]
- Dong, S.; Duan, Y.; Hu, Y.; Zhao, Z. Advances in the pathogenesis of Alzheimer’s disease: A re-evaluation of amyloid cascade hypothesis. Transl. Neurodegener. 2012, 1, 18. [Google Scholar] [CrossRef] [Green Version]
- Shannon, K.M. Huntington’s disease—Clinical signs, symptoms, presymptomatic diagnosis, and diagnosis. Handb. Clin. Neurol. 2011, 100, 3–13. [Google Scholar] [CrossRef] [PubMed]
- Ross, C.A.; Aylward, E.H.; Wild, E.J.; Langbehn, D.R.; Long, J.D.; Warner, J.H.; Scahill, R.I.; Leavitt, B.R.; Stout, J.C.; Paulsen, J.S.; et al. Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 2014, 10, 204–216. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walker, F.O. Huntington’s disease. Lancet 2007, 369, 218–228. [Google Scholar] [CrossRef] [PubMed]
- The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993, 72, 971–983. [Google Scholar] [CrossRef] [PubMed]
- Duyao, M.P.; Auerbach, A.B.; Ryan, A.; Persichetti, F.; Barnes, G.T.; McNeil, S.M.; Ge, P.; Vonsattel, J.P.; Gusella, J.F.; Joyner, A.L.; et al. Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 1995, 269, 407–410. [Google Scholar] [CrossRef] [PubMed]
- Zeitlin, S.; Liu, J.P.; Chapman, D.L.; Papaioannou, V.E.; Efstratiadis, A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. Nat. Genet. 1995, 11, 155–163. [Google Scholar] [CrossRef] [PubMed]
- Nasir, J.; Floresco, S.B.; O’Kusky, J.R.; Diewert, V.M.; Richman, J.M.; Zeisler, J.; Borowski, A.; Marth, J.D.; Phillips, A.G.; Hayden, M.R. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81, 811–823. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Karlovich, C.A.; John, R.M.; Ramirez, L.; Stainier, D.Y.; Myers, R.M. Characterization of the Huntington’s disease (HD) gene homologue in the zebrafish Danio rerio. Gene 1998, 217, 117–125. [Google Scholar] [CrossRef] [PubMed]
- Lumsden, A.L.; Henshall, T.L.; Dayan, S.; Lardelli, M.T.; Richards, R.I. Huntingtin-deficient zebrafish exhibit defects in iron utilization and development. Hum. Mol. Genet. 2007, 16, 1905–1920. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Henshall, T.L.; Tucker, B.; Lumsden, A.L.; Nornes, S.; Lardelli, M.T.; Richards, R.I. Selective neuronal requirement for huntingtin in the developing zebrafish. Hum. Mol. Genet. 2009, 18, 4830–4842. [Google Scholar] [CrossRef] [Green Version]
- Diekmann, H.; Anichtchik, O.; Fleming, A.; Futter, M.; Goldsmith, P.; Roach, A.; Rubinsztein, D.C. Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish. J. Neurosci. 2009, 29, 1343–1349. [Google Scholar] [CrossRef] [Green Version]
- Schiffer, N.W.; Broadley, S.A.; Hirschberger, T.; Tavan, P.; Kretzschmar, H.A.; Giese, A.; Haass, C.; Hartl, F.U.; Schmid, B. Identification of anti-prion compounds as efficient inhibitors of polyglutamine protein aggregation in a zebrafish model. J. Biol. Chem. 2007, 282, 9195–9203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Williams, A.; Sarkar, S.; Cuddon, P.; Ttofi, E.K.; Saiki, S.; Siddiqi, F.H.; Jahreiss, L.; Fleming, A.; Pask, D.; Goldsmith, P.; et al. Novel targets for Huntington’s disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol. 2008, 4, 295–305. [Google Scholar] [CrossRef] [Green Version]
- Veldman, M.B.; Rios-Galdamez, Y.; Lu, X.H.; Gu, X.; Qin, W.; Li, S.; Yang, X.W.; Lin, S. The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model. Mol. Neurodegener. 2015, 10, 67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- VerPlank, J.J.S.; Tyrkalska, S.D.; Fleming, A.; Rubinsztein, D.C.; Goldberg, A.L. cGMP via PKG activates 26S proteasomes and enhances degradation of proteins, including ones that cause neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 2020, 117, 14220–14230. [Google Scholar] [CrossRef] [PubMed]
- Renton, A.E.; Majounie, E.; Waite, A.; Simon-Sanchez, J.; Rollinson, S.; Gibbs, J.R.; Schymick, J.C.; Laaksovirta, H.; van Swieten, J.C.; Myllykangas, L.; et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron 2011, 72, 257–268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sullivan, P.M.; Zhou, X.; Robins, A.M.; Paushter, D.H.; Kim, D.; Smolka, M.B.; Hu, F. The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway. Acta Neuropathol. Commun. 2016, 4, 51. [Google Scholar] [CrossRef] [Green Version]
- Shaw, M.P.; Higginbottom, A.; McGown, A.; Castelli, L.M.; James, E.; Hautbergue, G.M.; Shaw, P.J.; Ramesh, T.M. Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features. Acta Neuropathol. Commun. 2018, 6, 125. [Google Scholar] [CrossRef] [Green Version]
- Ohki, Y.; Wenninger-Weinzierl, A.; Hruscha, A.; Asakawa, K.; Kawakami, K.; Haass, C.; Edbauer, D.; Schmid, B. Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration. Mol. Neurodegener. 2017, 12, 6. [Google Scholar] [CrossRef] [Green Version]
- Yeh, T.H.; Liu, H.F.; Li, Y.W.; Lu, C.S.; Shih, H.Y.; Chiu, C.C.; Lin, S.J.; Huang, Y.C.; Cheng, Y.C. C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Exp. Neurol. 2018, 304, 114–124. [Google Scholar] [CrossRef]
- McGown, A.; Shaw, D.P.J.; Ramesh, T. ZNStress: A high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. Mol. Neurodegener. 2016, 11, 56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Namikawa, K.; Dorigo, A.; Zagrebelsky, M.; Russo, G.; Kirmann, T.; Fahr, W.; Dübel, S.; Korte, M.; Köster, R.W. Modeling Neurodegenerative Spinocerebellar Ataxia Type 13 in Zebrafish Using a Purkinje Neuron Specific Tunable Coexpression System. J. Neurosci. 2019, 39, 3948–3969. [Google Scholar] [CrossRef] [Green Version]
- Namikawa, K.; Dorigo, A.; Köster, R.W. Neurological Disease Modelling for Spinocerebellar Ataxia Using Zebrafish. J. Exp. Neurosci. 2019, 13, 1179069519880515. [Google Scholar] [CrossRef] [Green Version]
- Lin, Y.; Cai, X.; Wang, G.; Ouyang, G.; Cao, H. Model construction of Niemann-Pick type C disease in zebrafish. Biol. Chem. 2018, 399, 903–910. [Google Scholar] [CrossRef] [PubMed]
- Uemura, N.; Koike, M.; Ansai, S.; Kinoshita, M.; Ishikawa-Fujiwara, T.; Matsui, H.; Naruse, K.; Sakamoto, N.; Uchiyama, Y.; Todo, T.; et al. Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein. PLoS Genet. 2015, 11, e1005065. [Google Scholar] [CrossRef] [PubMed]
Method | Phenotype | Results | Reference |
---|---|---|---|
MPTP induced | Motor impairments and weakened touch sensory | Reduction of locomotor activity and dopaminergic neuron, over-expression of synuclein in the optic tectum | [33,34,35,36] |
6-OHDA induced | Motor impairments and anxiety | Reduction of dopaminergic neurons and morphological alternations | [37,38,39,40] |
Paraquat induced | Motor impairments, various developmental anomalies | The paraquat-treated zebrafish did not recapitulate PD pathology | [41,42,43,44] |
Rotenone induced | Motor impairments, anxiety, and olfactory dysfunction | In addition to motor impairments, they also show Olfactory dysfunction, which is a typical non-motor symptom of PD | [45,46,47,48] |
PARK2 Morpholino | No abnormalities in swimming behavior | Loss of the DA neuron numbers in the diencephalon, whereas no abnormalities in swimming behavior | [49,50] |
PINK1 Morpholino; Transgenes | Motor impairment and oxidative stress | Reduction of dopaminergic neurons, dis-organized diencephalic dopaminergic neurons, and the pink1 gene are sensitive markers of oxidative stress in zebrafish | [51,52] |
LRRK2 Morpholino | Motor impairment | Loss of neuronal cells and synuclein aggregation, similar to the phenotype of PD in humans | [53,54,55,56] |
PARK7 Morpholino; CRISPR/Cas9 | Motor impairment | With aging, exhibit lower TH levels, respiratory failure in skeletal muscle, and lower body mass, particularly in the male fish | [57,58,59,60] |
Synuclein Transgenes | Motor impairment | Led to cell death in larval zebrafish sensory neurons | [61] |
GBA TALEN | Motor impairment | Reduction of the GBA protein, dopaminergic, and noradrenergic neurons | [62,63] |
PARL Morpholino; CRISPR/Cas9 | Motor impairment and olfactory dysfunction | Reduced DA neuronal population and dysregulation of the PINK1/Parkin mitophagy pathway | [64,65] |
Method | Phenotype | Results | Reference |
---|---|---|---|
Amyloid-β42 induced | Intracellular depositions | Link between aging, neurogenesis, regenerative, neuroinflammation, and neural stem cell plasticity | [99,100] |
Okadaic acid induced | Cognitive and memory impairments, neuroinflammation cholinergic dysfunction, glutamate excitotoxicity, and mitochondrial dysfunction | Provide all the major molecular hallmarks of AD | [101,102,103] |
Cigarette smoke extract induced | Neurocognitive dysfunction | Enhancement of the acetylcholinesterase activity | [104,105] |
Aluminum chloride induced | Neurocognitive dysfunction, memory impairment | Impaired locomotor activity, learning, and memory abilities | [106] |
Copper induced | Memory impairment | Reduction of the glutathione S-transferase (GST) activity in the gill | [107] |
MnCl2 induced | Cognition and exploratory behavior | Impairment of aversive long-term memory and distance traveled movement time | [108] |
MAPT Transgenes | Motor impairment | The phenotypic abnormalities at larval stages make it suitable for high-throughput screening | [109,110] |
PSEN1 ENU-mutagenized | Motor impairment | Regulation of histaminergic neuron development | [111] |
BACE1/2 zinc finger nuclease; ENU-mutagenized | Hypomyelination, supernumery neuromasts, and abnormal pigmentation | Bace1 and Bace2 are proteases with different physiological functions | [112] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Wang, J.; Cao, H. Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases. Int. J. Mol. Sci. 2021, 22, 10766. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms221910766
Wang J, Cao H. Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases. International Journal of Molecular Sciences. 2021; 22(19):10766. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms221910766
Chicago/Turabian StyleWang, Jing, and Hong Cao. 2021. "Zebrafish and Medaka: Important Animal Models for Human Neurodegenerative Diseases" International Journal of Molecular Sciences 22, no. 19: 10766. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms221910766